RxDoctor Payments Data

Jonathan White, MD

Gastroenterology · Meriden, CTNPI 1598893224

Payments from drug & device makers

$2,498in general payments, 2019–2025

Across 140 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$966
  • Covidien LP$241
  • Takeda Pharmaceuticals U.S.A., Inc.$232
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$203
  • Ardelyx, Inc.$159
  • Gilead$140
  • plus $557 from 18 others

What the payments were for

  • Travel & lodging$1506%
  • Food & beverage$2,33293%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,498 in reported general payments places this provider in the 40th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$74,413
Medicare patients
238
Services billed
1,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab33$911,189
LinzessLinaclotide134$118,948
CreonLipase/Protease/Amylase18$55,913
Mesalamine80$55,573
XifaxanRifaximin15$47,057
MotegrityPrucalopride Succinate23$16,577
NexiumEsomeprazole Magnesium25$15,506
Dexlansoprazole DrDexlansoprazole60$14,955
TrulancePlecanatide20$12,052
SutabSod Sulf/Pot Chloride/Mag Sulf69$11,343
Pantoprazole Sodium257$7,823
ClenpiqSod Picosulf/Mag Ox/Citric Ac42$7,292
Omeprazole400$5,911
Sucralfate40$4,966
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates71$4,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$51$911,18933 claims
AbbVieLinzess, Creon$966$174,861152 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$203$59,10935 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$232$16,57723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Meriden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →